Cross-protective immunity following coronavirus vaccination and coronavirus infection
Authors:
- Tanushree DangiTDTanushree Dangi
- Nicole PalacioNPNicole Palacio
- Sarah SanchezSSSarah Sanchez
- Mincheol ParkMPMincheol Park
- Lavanya VisvabharathyLVLavanya Visvabharathy
- Thomas CiucciTCThomas Ciucci
- Igor J. KoralnikIKIgor J. Koralnik
- Justin M. RichnerJustin M. Richner
- Pablo Penaloza-MacMasterPPPablo Penaloza-MacMaster
- 15 December 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (24)
Abstract
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have shown efficacy against SARS-CoV-2, it is unknown if coronavirus vaccines can also protect against other coronaviruses that may infect humans in the future. Here, we show that coronavirus vaccines elicited cross-protective immune responses against heterologous coronaviruses. In particular, we show that a severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) vaccine developed in 2004 and known to protect against SARS-CoV-1 conferred robust heterologous protection against SARS-CoV-2 in mice. Similarly, prior coronavirus infections conferred heterologous protection against distinct coronaviruses. Cross-reactive immunity was also reported in patients with coronavirus disease 2019 (COVID-19) and in individuals who received SARS-CoV-2 vaccines, and transfer of plasma from these individuals into mice improved protection against coronavirus challenges. These findings provide the first demonstration to our knowledge that coronavirus vaccines (and prior coronavirus infections) can confer broad protection against heterologous coronaviruses and establish a rationale for universal coronavirus vaccines.Keywords
Funding Information
- National Institute on Drug Abuse (DP2DA051912)
This publication has 28 references indexed in Scilit:
- Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in MiceCell Host & Microbe, 2020
- Interrogating Adaptive Immunity Using LCMVCurrent Protocols in Immunology, 2020
- scRepertoire: An R-based toolkit for single-cell immune receptor analysisF1000Research, 2020
- NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand dataNucleic Acids Research, 2020
- Dose Effects of Recombinant Adenovirus Immunization in RodentsVaccines, 2019
- Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 VectorsJournal of Virology, 2013
- Coronaviruses: Propagation, Quantification, Storage, and Construction of Recombinant Mouse Hepatitis VirusCurrent Protocols in Microbiology, 2011
- Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike proteinVirology, 2005
- Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding RegionJournal of Virology, 2005
- Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceProceedings of the National Academy of Sciences, 2004